Literature DB >> 9782052

Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.

R Baumgartner1, C Fernandez-Catalan, A Winoto, R Huber, R A Engh, T A Holak.   

Abstract

BACKGROUND: The four members of the INK4 gene family (p16(INK4a), p15(INK4b), p18(INK4c) and p19(INK4d)) inhibit the closely related cyclin-dependent kinases CDK4 and CDK6 as part of the regulation of the G1-->S transition in the cell-division cycle. Loss of INK4 gene product function, particularly that of p16(INK4a), is found in 10-60% of human tumors, suggesting that broadly applicable anticancer therapies might be based on restoration of p16(INK4a) CDK inhibitory function. Although much less frequent, defects of p19(INK4d) have also been associated with human cancer (osteosarcomas). The protein structures of some INK4 family members, determined by nuclear magnetic resonance (NMR) spectroscopy and X-ray techniques, have begun to clarify the functional role of p16(INK4a) and the dysfunction introduced by the mutations associated with human tumors.
RESULTS: The crystal structure of human p19(INK4d) has been determined at 1.8 A resolution using multiple isomorphous replacement methods. The fold of p19(INK4d) produces an oblong molecule comprising five approximately 32-residue ankyrin-like repeats. The architecture of the protein demonstrates the high structural similarity within the INK4 family. Comparisons to other ankyrin-repeat-containing proteins (GABPbeta, 53BP2 and myotrophin) show similar structures with comparable hydrogen-bonding patterns and hydrophobic interactions. Such comparisons highlight the splayed beta-loop geometry that is specific to INK4 inhibitors. This geometry is the result of a modified ankyrin structure in the second repeat.
CONCLUSIONS: Among the INK4 inhibitors, the highest amino acid sequence conservation is found in the helical stacks; this conservation creates a conserved beta-loop geometry specific to INK4 inhibitors. Therefore, in addition to models which predict that the conserved helix alpha6 is responsible for CDK inhibition, a binding mode whereby the loops of INK4 proteins bind to the CDKs should also be considered. A similar loop-based interaction is seen in the complex formed between the ankyrin-repeat-containing protein GABPbeta and_GABPalpha. This mode of binding would be consistent with the observation that p16(INK4a) is sensitive to deleterious mutations found throughout this tumor suppressor protein; these mutations probably destabilize the three-dimensional structure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9782052     DOI: 10.1016/s0969-2126(98)00128-2

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  14 in total

1.  Crystal structure of a 12 ANK repeat stack from human ankyrinR.

Authors:  Peter Michaely; Diana R Tomchick; Mischa Machius; Richard G W Anderson
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

Review 2.  Utilizing NMR to study the structure of growth-inhibitory proteins.

Authors:  Francesca Marassi
Journal:  Methods Mol Biol       Date:  2003

3.  Designed to be stable: crystal structure of a consensus ankyrin repeat protein.

Authors:  Andreas Kohl; H Kaspar Binz; Patrik Forrer; Michael T Stumpp; Andreas Plückthun; Markus G Grütter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-03       Impact factor: 11.205

4.  Two novel transcripts encoding two Ankyrin repeat containing proteins have preponderant expression during the mouse spermatogenesis.

Authors:  Fei Wang; Jiarui Hu; Ping Song; Wuming Gong
Journal:  Mol Biol Rep       Date:  2006-12-15       Impact factor: 2.316

5.  Phosphorylation-induced unfolding regulates p19INK4d during the human cell cycle.

Authors:  Amit Kumar; Mohanraj Gopalswamy; Annika Wolf; David J Brockwell; Mechthild Hatzfeld; Jochen Balbach
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

6.  Tumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR data.

Authors:  C Yuan; T L Selby; J Li; I J Byeon; M D Tsai
Journal:  Protein Sci       Date:  2000-06       Impact factor: 6.725

7.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.

Authors:  Sunita K Agarwal; Carmen M Mateo; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

Review 8.  Lessons from the genome sequence of Neurospora crassa: tracing the path from genomic blueprint to multicellular organism.

Authors:  Katherine A Borkovich; Lisa A Alex; Oded Yarden; Michael Freitag; Gloria E Turner; Nick D Read; Stephan Seiler; Deborah Bell-Pedersen; John Paietta; Nora Plesofsky; Michael Plamann; Marta Goodrich-Tanrikulu; Ulrich Schulte; Gertrud Mannhaupt; Frank E Nargang; Alan Radford; Claude Selitrennikoff; James E Galagan; Jay C Dunlap; Jennifer J Loros; David Catcheside; Hirokazu Inoue; Rodolfo Aramayo; Michael Polymenis; Eric U Selker; Matthew S Sachs; George A Marzluf; Ian Paulsen; Rowland Davis; Daniel J Ebbole; Alex Zelter; Eric R Kalkman; Rebecca O'Rourke; Frederick Bowring; Jane Yeadon; Chizu Ishii; Keiichiro Suzuki; Wataru Sakai; Robert Pratt
Journal:  Microbiol Mol Biol Rev       Date:  2004-03       Impact factor: 11.056

9.  Disruption of G1-phase phospholipid turnover by inhibition of Ca2+-independent phospholipase A2 induces a p53-dependent cell-cycle arrest in G1 phase.

Authors:  Xu Hannah Zhang; Chunying Zhao; Konstantin Seleznev; Keying Song; James J Manfredi; Zhongmin Alex Ma
Journal:  J Cell Sci       Date:  2006-02-21       Impact factor: 5.285

10.  Disruption of chromosome 11 in canine fibrosarcomas highlights an unusual variability of CDKN2B in dogs.

Authors:  Jesús Aguirre-Hernández; Bruce S Milne; Chris Queen; Patricia C M O'Brien; Tess Hoather; Sean Haugland; Malcolm A Ferguson-Smith; Jane M Dobson; David R Sargan
Journal:  BMC Vet Res       Date:  2009-07-31       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.